RPID — Rapid Micro Biosystems, Inc.

Summary of Rapid Micro Biosystems Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $7.8 million, a 3% increase from $7.6 million in Q3 2024, exceeding guidance.
• Product Revenue: $5.2 million, flat year-over-year, with record consumable revenue up 40%.
• Service Revenue: $2.6 million, a 12% increase year-over-year.
• Recurring Revenue: Increased 32% to $4.8 million, driven by consumables and service contracts.
• Gross Margin: 9%, a 70 basis point improvement year-over-year; service margins at 40%.
• Net Loss: $11.5 million, consistent with the previous year’s loss of $11.3 million.
• Cash Position: Approximately $42 million at the end of the quarter.

2. Strategic Updates and Business Highlights

• Record Multi-System Order: Secured from a top 20 global biopharma customer, expected to contribute to revenue in Q4 and 2026.
• Growth Direct Platform: Strong customer interest, with significant adoption across multiple manufacturing modalities.
• MilliporeSigma Partnership: Progressing well, with initial orders for Growth Direct Systems and ongoing material validation studies aimed at cost efficiencies.
• Industry Engagement: Participation in the PDA Pharmaceutical Microbiology Conference highlighted the trend towards automation in pharmaceutical manufacturing.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to at least $33 million for 2025, including at least 27 Growth Direct System placements.
• Q4 Expectations: Anticipate a decrease in consumable revenue sequentially; service revenue expected to drop to around $2 million due to timing of validation activities.
• Gross Margin Outlook: Expected to be in the mid-single digits for Q4, with positive product margins anticipated for the first time.
• 2026 Projections: Continued gross margin improvement expected, driven by cost reductions, increased volume leverage, and benefits from the MilliporeSigma collaboration.

4. Bad News, Challenges, or Points of Concern

• Service Revenue Decline: Expected decrease in Q4 service revenue due to timing of validation activities, which may impact short-term financial performance.
• Product Margins: Negative product margins reported, although improvements are anticipated in the coming quarters.
• Market Conditions: While demand remains steady, budget scrutiny in the pharma sector could impact future spending and order placements.

5. Notable Q&A Insights

• Clarification on Guidance: The increase in revenue guidance was attributed to the recent multi-system order, which was not included in previous forecasts.
• Geographical Demand: Demand remains consistent across North America, Europe, and Asia, with no significant regional advantages noted.
• Onshoring Impact: Expected to be a gradual benefit, with potential growth in 2026 and beyond, rather than an immediate surge.
• Adjacent Market Penetration: Focus on personal care and other markets is primarily through the collaboration with MilliporeSigma, leveraging their global sales force.

This summary encapsulates the key takeaways from Rapid Micro Biosystems' Q3 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.